Azintuxizumab vedotin

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells. Azintuxizumab vedotin is composed of an anti-CD2, IgG1κ, antibody, an enzymatically cleavable peptide-linker, the cytotoxic agent Monomethyl auristatin E (MMAE). Sofituzumab Vedotin has a Drug-to-antibody ratio (DAR) of 4, it shows single-agent antitumor activity in mouse models using human myeloma xenografts. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Azintuxizumab (anti-CD2)
ADC cytotoxin (drug)	MMAE
Immunogen	Human CD2
DAR (Drug to Antibody Ratio)	~ 4.0
Purity	98%
Molecular Weight	N/A
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	1xPBS